Session Information
Date: Wednesday, June 7, 2017
Session Title: Parkinson's Disease: Cognition
Session Time: 1:15pm-2:45pm
Location: Exhibit Hall C
Objective: We examined the effect of dopaminergic medication on executive function in 24 drug-naïve PD patients (de novo group) and in 21 PD patients on chronic dopaminergic medication (chronic medication group).
Background: Executive function is influenced by dopaminergic medication. However the effects of dopaminergic medication on executive function in Parkinson’s disease (PD) patients are inconsistent.
Methods: PD patients without dementia were included in this study. For the de novo group patients, dopaminergic medication was initiated, and the dose was increased to improve motor symptoms. For the chronic medication group patients, dopaminergic medication was adjusted to relieve clinical problems, such as hallucinations. All participants were tested prior to and at 4 to 7 months after the drug initiation/adjustment. Executive function was assessed using the Behavioral Assessment of the Dysexecutive syndrome (BADS) score. Motor function was assessed using the Unified Parkinson’s Disease Rating Scale (UPDRS) part III. Improvement in executive function was compared with a simultaneous change in levodopa equivalent doses (LED) of dopaminergic medication and with improvement in motor functions.
Results: The mean standardized BADS scores showed no significant improvement in both groups. However, in the de novo group, improvement in the standardized BADS score showed a significant positive correlation with the LED (p<0.001) and tended to correlate with motor improvement (p=0.07). In the chronic medication group, improvement in the standardized BADS score significantly correlated with motor improvement (p<0.05) and tended to negatively correlate with change in the LED (p=0.06).
Conclusions: Effects of dopaminergic medication on executive function differ according to the patient’s clinical stage and depend on the LED in the de novo stage.
To cite this abstract in AMA style:
H. Murakami, M. Kezuka, R. Kon, M. Kawamura, K. Ono. Effects of dopaminergic medication on executive function in Parkinson’s disease differs according to the clinical stage [abstract]. Mov Disord. 2017; 32 (suppl 2). https://www.mdsabstracts.org/abstract/effects-of-dopaminergic-medication-on-executive-function-in-parkinsons-disease-differs-according-to-the-clinical-stage/. Accessed June 15, 2025.« Back to 2017 International Congress
MDS Abstracts - https://www.mdsabstracts.org/abstract/effects-of-dopaminergic-medication-on-executive-function-in-parkinsons-disease-differs-according-to-the-clinical-stage/